Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02476942 · ClinicalTrials.gov registry record
A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
A clinical trial, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- 221
- Enrollment target
NCT02476942: Completed study, sponsored by Hoffmann-La Roche.
NCT02476942 is a clinical trial that has completed, run by Hoffmann-La Roche. The registered enrollment target is 221 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02476942 has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- 221 participants
- Enrollment target
Study Summary
This non-interventional study will prospectively collect detailed, high-quality documentation of bleeds, HRQoL, and safety in patients with hemophilia A with or without FVIII inhibitors treated according to local routine clinical practice (receiving FVIII replacement or bypassing agents as either episodic or prophylactic treatment). Actual patients will be enrolled from routine clinical practice in this observational study.
Interventions
- DRUG Bypassing Agents
- DRUG FVIII Replacement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2015-05-26 |
| Est. Completion | 2017-03-31 |
What the finished NCT02476942 record still lists
NCT02476942 is an observational study that tracks outcomes without assigning an intervention. The registered 221 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Bypassing Agents is the first listed.
NCT02476942 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02476942 about?
NCT02476942 is a clinical study titled "A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment". This non-interventional study will prospectively collect detailed, high-quality documentation of bleeds, HRQoL, and safety in patients with hemophilia A with or without FVIII inhibitors treated according to local routine clinical practice (receiving FVIII replacement or bypassing agents as either ep...
What is the current status of trial NCT02476942?
This trial is currently completed. The enrollment target is 221 participants. The study started on 2015-05-26. Estimated completion is 2017-03-31.
What interventions are being tested in trial NCT02476942?
The interventions under investigation include: Bypassing Agents (DRUG), FVIII Replacement (DRUG).
Who is sponsoring clinical trial NCT02476942?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03170440 · 221 participants · NA
Non-invasive Nerve Stimulation for PTSD and Sleep
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI